Literature DB >> 19258231

Antiepileptic drugs and psychopathology of epilepsy: an update.

Marco Mula1, Francesco Monaco.   

Abstract

Anti-epileptic drugs (AEDs) continue to be the mainstay of epilepsy treatment, but the benefits of seizure control need to be weighed carefully against possible adverse effects, which can include behavioral problems and psychiatric disorders. In this paper, the associations between AEDs and psychosis, depression and behavioral changes are reviewed. The concept of forced normalization and its clinical counterpart, alternative psychosis, are also discussed. Depression seems to be linked with AEDs potentiating GABAergic neurotransmission in patients with limbic system abnormalities such as hippocampal sclerosis. Psychoses have been described as associated with several of the new AEDs, and they are often seen in a setting in which previously refractory patients suddenly become seizure-free. In general terms, the use of AEDs in monotherapy, adopting slow titration schedules and low doses when possible, can significantly reduce the occurrence of behavioral adverse effects. A previous history of psychiatric disorder or a familial predisposition are important risk factors and should be always considered when choosing the appropriate AED.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258231     DOI: 10.1684/epd.2009.0238

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  30 in total

Review 1.  Depression in epilepsy: a critical review from a clinical perspective.

Authors:  Christian Hoppe; Christian E Elger
Journal:  Nat Rev Neurol       Date:  2011-07-12       Impact factor: 42.937

2.  Children with epilepsy and anxiety: Subcortical and cortical differences.

Authors:  Jana E Jones; Daren C Jackson; Karlee L Chambers; Kevin Dabbs; David A Hsu; Carl E Stafstrom; Michael Seidenberg; Bruce P Hermann
Journal:  Epilepsia       Date:  2015-01-12       Impact factor: 5.864

3.  Down syndrome and dementia: seizures and cognitive decline.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Nina Movsesyan; Daniel L Gillen
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan.

Authors:  Jack J Lin; Marco Mula; Bruce P Hermann
Journal:  Lancet       Date:  2012-09-29       Impact factor: 79.321

5.  Development of forced normalisation psychosis with ethosuximide.

Authors:  Sean Apap Mangion; Fergus Rugg-Gunn
Journal:  BMJ Case Rep       Date:  2017-12-07

Review 6.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 7.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

8.  FORCED NORMALIZATION: Epilepsy and Psychosis Interaction.

Authors:  Muruga A Loganathan; Manasa Enja; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

9.  Recurrent schizophrenia-like psychosis as first manifestation of epilepsy: a diagnostic challenge in neuropsychiatry.

Authors:  Willem M A Verhoeven; Jos I M Egger; W Boudewijn Gunning; Martijn Bevers; Boudewijn J H B de Pont
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

Review 10.  Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.

Authors:  Sheridan M Hoy
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.